Are beta2-Adrenergic Receptor Gene Single-Nucleotide Polymorphism
Gynecology & Obstetrics

Gynecology & Obstetrics
Open Access

ISSN: 2161-0932

Research Article - (2015) Volume 5, Issue 12

Are beta2-Adrenergic Receptor Gene Single-Nucleotide Polymorphisms Associated with Polycystic Ovary Syndrome? a Pharmacogenetic Study

Jafarian T1, Naghizadeh MM2, Salmani A3, Nejad Fathe Moghadam S1 and Zangeneh FZ4*
1Biology Department, Pharmaceutical Science Branch, Islamic Azad University, Tehran, Iran
2Department of Community Medicine, Medical Faculty, Fasa University of Medical Sciences, Fasa, Iran
3Department of Genetics, Mashad University of Medical Sciences, Mashad, Iran
4Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran
*Corresponding Author: Zangeneh FZ, Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran, Tel: +989123752767 Email:


Study background: Polycystic ovary syndrome (PCOS) is a common complex condition in women associated with reproductive, metabolic and psychological features. Evidences from studies on women with PCOS and on an experimental rat PCO model suggest that the sympathetic regulatory drive to the ovary may be unbalanced (hyperactivity). The aim of this study was to investigate polymorphism codon 16, 27,113 and 164 of beta2 adrenergic receptor in polycystic ovary syndrome (PCOS).

Methods: 100 patients with PCOS from Infertility Center of Valie Asre, Imam Khomeini Hospital Complex participated in this study for the first time between May 2014-2015. All women aged 20-40 years and had a body mass index (BMI) were under 28.

Results: Our results show that women with PCOS had polymorphism only in codon 164 with 44.4% (P< 0.002), that represents a significant difference between the study and control groups.

Conclusion: Therefore Beta2 adrenergic receptor gene polymorphism (Thr164Ile) associates withpolycystic ovary syndrome. The ratio of heterozygotes to homozygotes shows a significant difference between the two groups.

Keywords: Polycystic ovary syndrome (PCOS); Beta-2 adrenergic receptor gene polymorphism; Heterozygotes; Homozygotes


Polycystic ovary syndrome (PCOS) is a multifactorial, heterogeneous, complex genetic, endocrine and metabolic disorder, diagnostically characterized by chronic anovulation. The autonomic nervous system plays an important role in the regulation of ovarian physiology [1,2]. It is well known that one of the major neurotransmitters that control LH secretion is noradrenaline (NA). As women with PCOS have significantly higher sympathetic nerve activity than their matched controls, the increased sympathetic outflow may be related to hormonal and metabolic features that may be relevant to the pathophysiology of the syndrome [3]. Rodent models of polycystic ovaries have shown that ovarian sympathetic outflow may be increased [4,5] transection of the superior ovarian nerve in the EV-induced rat PCO model reduces the steroid response, increases b2-adrenoceptor expression to more normal levels, and restores estrus cyclicity and ovulation [6]. Consequently, the identification of genes related to PCOS is complicated by the heterogeneity of its etiology. Studies identifying familial clustering of cases have established a genetic basis of PCOS [7]. Evidence suggests it to be a complex heterogeneous syndrome in which both genetic and environmental influences play an important role in its manifestation. Beta2-adrenergic receptor may represent a functional candidate gene.

Beta2 adrenergic receptor

The gene encoding ADRB2 displays a moderate degree of heterogeneity in the human population and the distributions of singlenucleotide polymorphisms (SNPs) at amino acid positions 16, 27, and 164 are changed in asthma, obesity, and hypertension and in the autoimmune disease myasthenia gravis [8,9]. An involvement of the beta2-AR has also been suggested in human rheumatoid arthritis (RA) and its animal model. The ADRB2 gene has 9 different single nucleotide polymorphisms (SNPs); in which, four of these polymorphisms involve the change of amino acids at residues 16, 27, 34 and 164 [10]. Numerous reports have suggested possible associations between SNPs in the coding region of the ADRB2, mostly for Arg16Gly, Gln27Glu and Threonine 16 Isoleucine (Thr164Ile), but have produced conflicting results [11,12]. This polymorphism has been studied in a transfected cell system and has been shown to alter the agonist-binding properties of the receptor (Figure 1).


Figure 1: The structure of the human β2-receptor and the sites of polymorphic mutations of the receptor are shown in image.

Adrb2 variants and functional studies

Individual variations in physiological responses, expression and function of Adrb2, as well as individual differences in response to drugs that act on these receptors may relate to polymorphic variants of the receptor [13]. The Adrb2 regulates a number of metabolic and physiologic processes in various organs such as heart, lung and kidney [14]. While variation of Valine to Methionine at codon 34 (Val34Met) and Threonine to Isoleucine at codon 164 (Thr164Ile) are rare mutations [10,15]. A number of reports revealed that both the Arg16Gly and Gln27Glu variants may play a role in receptor down regulation. In studies among asthmatic patients, Arg16Gly substitution exaggerates agonist-mediated receptor down-regulation in response to β2 agonists [16]. In another experiments, the Isoleucine substitution of the Threonine in residue 164 causes that receptor to have decreased basal and agonist-stimulated adenylyl cyclase activities and therefore, decreased affinity for β2 agonists [17].

Adrb2 Variants and PCOS

Waterworth et al., first reported a strong linkage and association between the III/III genotype of INS VNTR and anovulatory PCOS [18]. Several studies have since looked for association of these VNTRs with PCOS and related phenotypes in different ethnic populations. Vanková et al., found no association with PCOS or related traits like BMI, insulin, glucose, or c-peptide levels [19]. Ferk et al., reported a significant association of class III INS VNTR alleles with PCOS and obese women with III/III INS VNTR genotype showed elevated insulin levels [20]. Similar associations with PCOS were not observed in Finnish [21], Croatian [22], Korean [23], and Han Chinese [24] populations. Recent meta-analysis confirmed a strong association of INS VNTR polymorphism with PCOS risk only in anovulatory women but not with the overall women with PCOS which may explain the contradictory results mentioned above [25]. Sheikh et al., reviewed Genetic Markers of PCOS on insulin resistance. They summarized the role of putative genetic variants contributing to the insulin resistance state frequently observed in PCO women [26]. These studies help to understand complex phenotypes of PCOS and are useful for in designing of therapies approaches. The aim of this study was to investigate polymorphism codon 16, 27,113 and 164 of beta2 adrenergic receptor in polycystic ovary syndrome (PCOS). The reason for choosing of these codons is the role of them in diseases associated with hyperactivity of the SAS, which has been reported till now. In this study, we investigated them in PCOS.

Materials and Methods


This Case/control study was carried out at May 2014-2015. Totally 103 PCO patients from Reproductive Health Research Center of Imam Khomeini Hospital, Tehran, Iran participated in this study. In this study inclusion criteria were aged 20-40 years and the body mass index (BMI) fewer than 28 and exclusion criteria were no specific disease and no drugs for all women. The diagnosis of PCOS was made according to the joint criteria of the European Society of Human Reproduction and Embryology and the American Society of Reproductive Medicine (ESHRE/ASRM) [27]. Two out of three of the following criteria were met for the diagnosis: oligo-ovulation and/or anovulation (irregular menstrual cycle), clinical and/or biochemical signs of hyperandrogenism, polycystic ovaries (PCO) by ultrasound (≥ 12 or more follicles in each ovary measuring 2-8 mm in diameter). This study was approved by the Ethics Committee of Tehran University of Medical Sciences. The study objectives were explained to the patients before they entered the study, and an informed consent was obtained from all.


Preparation of peripheral blood samples of PCO and control groups. Blood samples were collected in EDTA treated tubes and maintained at -20°C.

DNA extraction

Total Genomic DNA was extracted from these samples by using Blood & cell culture kit, Qiagen (Iran) according to manufacturer's instructions. Purity and concentration of genomic DNA was evaluated using Nanodrop and prepared a concentration 50 μg/ml as working tubes. Primer had been designed for PCR-based gene bank.

Genotyping of ADRB2gene: amplification of sample for preparation of PCR

ADRB2 Information (NC_000005.10:148826593...14882863 4) was extracted from NCBI Site. ADRB2 functional SNPs was selected for genotyping in this study is rs180088 (Thr164Ile). The SNP genotypes were determined by polymerase chain reaction (PCR). PCR reactions were performed using specific primers was designed by Primer3 online software. PCR reactions were carried out in a volume of 25 μl using 1 μl of genomic DNA, 7 μl Master Mix(Taq DNA Polymerase 2X Master Mix Red, 1.5 mm MgCL2 ) , 15 μl ddH2O, 1 μl Forward primer and 1 μl Reverse primer was used. The primer pairs were: 5' AAGCGGCTTCTTCAGAGCA 3' (forward) and 5'-GATGGCTTCCTGGTGGGTG-3' (reverse). The generated PCR product size using these primers is 759 bp. Reaction buffers were those included with these polymerases from the manufacturers. Temperature cycling was 95°C for 5 min, 95°C for 3 s, 61°C for 30 s, 72°C for 20 s and 72°C for 5 min for 30 cycles. 5 μl of the PCR reactions were then electrophoresed on 1.5% agarose gels and visualized with ethidium bromide staining and ultraviolet illumination. The allele-specific PCR technique was verified by direct dideoxy sequencing of PCR products generated using sequencing primers different from those used in the PCR (Figure 2).


Figure 2: Jells electrophorese .

Statistical Analysis

Data was presented as frequency and percentage also odds ratio and 95% confidence interval. Comparison of mutation and zygote between PCO and control groups were done with chi-square test. Because unbalance and low sample size in control group a bootstrap estimation was used to check the hypothesis. Statistical analysis was done in SPSS 19 (SPSS Inc, Chicago, ILL). Statistical power of analysis was calculated with PASS (NCSS PASS program, NCSS, Kaysville, UT).


Sequencing results

Mutation in codon 27 was higher than other codon 70% but it was not significant difference with control group (Figure 3). All calculation approves this hypothesis that codon 27 mutation there is no significant difference between PCOs and normal women.


Figure 3: Sequencing of Codon27, CAA, mutant.

Mutation in codon 16 was 69.7%. It was not significant difference with control group. According to calculation we could not had any powerful inference about hypothesis, that codon 16 mutation was different between PCOs and normal women (Figure 4).


Figure 4: Sequencing of Codon16, CAA, mutant.

Mutation in codon 113 was 7% in PCOs women while it was not seen in control group because mutation in control group was not seen, calculation of power, odds ratio and bootstrapping method was not possible. If one woman with mutant gene added to control group, mutation rate in control group increase to 7.9%. Mutation rate in control comparison with 7% in PCOs group have not significant difference with good power. In other way if one woman without mutation added to control group, mutation rate in control comparison to PCOs group have not significant difference. We can show if 13 women without mutation add to control group mutation rate are not statistically significant differences. Finally we approve this hypothesis that mutation in codon 13 there is no significant difference between PCOs and normal women (Figure 5).


Figure 5: Sequencing of Codon113, GAT, normal.

Mutation rate in codon 164 in PCOs women was 44.4%. It was significantly higher than control group. If one woman without mutant gene added to control group, difference between two groups become deeply so it still be significant. In other way if one woman with mutation added to control group, mutation rate in control comparison to PCOs group have still be significant differences. Also if increase control groups to 16 women without mutation that significance in mutation rate will be remain. So we can reject this hypothesis that mutation in codon 164 there is no significant difference between PCOs and normal women (Figure 6). Comparison of mutation between PCO and normal women has shown in (Table 1).


Figure 6: Sequencing of Codon164, ATC, mutant.

  Control PCOs P-value
Chi square
Statistical power
n % n %
Codon 27 Wild 3 23.1% 30 30.0% 0.606 0.672
Mutant 10 76.9% 70 70.0%
Codon 16 Wild 7 53.8% 30 30.3% 0.090 0.482
Mutant 6 46.2% 69 69.7%
Codon 113 Wild 13 100.0% 93 93.0% 0.325 NC
Mutant 0 0.0% 7 7.0%
Codon 164 Wild 13 100.0% 55 55.6% 0.002 NC
Mutant 0 0.0% 44 44.4%

Table 1: Comparison of mutation at different codon in Beta2 adrenergic gene between PCO and normal women.

Zygote in codon 27 and 16 were significant difference with control group (Table 2).

  Control PCOs P-value
Chi square
n % n %
Codon 27 Heterozygote 6 46.2% 21 21.0% 0.045
Homozygote 7 53.8% 79 79.0%
Codon 16 Heterozygote 8 61.5% 23 23.2% 0.004
Homozygote 5 38.5% 76 76.8%
Codon 113 Heterozygote 0 0.0% 17 17.0% 0.107
Homozygote 13 100.0% 83 83.0%
Codon 164 Heterozygote 0 0.0% 7 7.1% 0.322
Homozygote 13 100.0% 92 92.9%

Table 2: Comparison of zygote in Beta2 adrenergic gen between PCO and normal women.

Our results show that women with PCOS had polymorphism only in codon 164 (P<0.002). Zygote in both codon 27 and 16 were significant difference in PCO and control group.


Studies on the β2-adrenoceptor identified a total of 9 different polymorphisms. All of these differed from the accepted wild-type sequence by a single base change at different positions in the coding sequence of the gene. Because of redundancy in the amino acid code, a number of these polymorphisms are clinically silent. However, 4 polymorphisms, resulting from single base changes, altered the amino acid sequence of the receptor protein [28].

The relationship between neuronal activity of b-adrenergic receptors and the stimulatory effect of noradrenaline (NA) on steroid secretion found in the ovary [29] gives further support for a regulatory and complementary role between gonadotropins and sympathetic nerves. Lara in 1993 found that PCO induced by the administration of a single dose of EV to rats results in profound changes in ovarian catecholamine homeostasis, which were initiated before the development of cysts and persist after the cysts were formed [30,31]. These changes include an increased ovarian NA content, enhanced NA release from ovarian nerve terminals and down-regulation of b-adrenergic receptors in theca-interstitial cells and in granulosa cells [32]. The β2-receptor is in the activated form when it is associated with the α-subunit of the Gs protein, together with a molecule of guanosine triphosphate (GTP). The replacement of the GTP by guanosine diphosphate dramatically reduces the affinity of the α-subunit for the receptor, causing dissociation and inducing the receptor to return to its low-energy inactivated form. It is probable that β2-agonists have their effects not through inducing a conformational change in the receptor but rather by binding to and temporarily stabilizing receptors in their activated state (ie, bound to Gs-GTP) [33]. Associated with b2-adrenoceptor activation is the autoregulatory process of receptor desensitization. This process operates as a safety device to prevent overstimulation of receptors in the face of excessive b2-agonist exposure. Desensitization occurs in response to the association of the receptor with the agonist molecule. The mechanisms by which desensitization can occur consist of 3 main processes: (1) uncoupling of the receptors from adenylate cyclase, (2) internalization of uncoupled receptors, and (3) phosphorylation of internalized receptors. The extent of desensitization depends on the degree and duration of the b2-adrenoceptor/b2- agonist response. The principal mechanism of homologous, shortterm b2-agonist–promoted desensitization of the b2-adrenoceptor is phosphorylation of the receptor by PKA, beta adrenoceptor kinase, or other closely related G protein–coupled receptor kinases [34]. Under experimental conditions, increased ovarian sympathetic tone in rat with EV-induced PCO has been evidenced by elevations in tyrosine hydroxylase activity and NA concentration, down-regulation of the b2- AR, and increased production of ovarian nerve growth factor, a target-derived neurotrophin [35]. Desensitization or down-regulation of beta2 adenoceptors can be accrue after more prolonged agonist exposure, an internalization of receptors occurs that results in some loss from the cell surface. This process, termed sequestration, might play a major role in short-term regulation of the receptor, because while sequestered, dephosphorylation of the receptor occurs (Figure 7) [36]. Internalization takes longer to reverse than uncoupling, but full reversal normally occurs within hours. Receptor trafficking as part of the overall process of receptor desensitization has now been investigated in the form of kinetic analysis of internalization and recycling of the human b2-receptor. Under resting conditions, recycling of the receptor reflects 1-phase exponential kinetics with a half-life of 7.5 minutes [28].


Figure 7: Beta2-Adrenoceptor trafficking. After b2-agonist binding, PKA, b-adrenoceptor kinase, or both phosphorylate the b2-receptor, leading to desensitization. b- Arrestin binding is stimulated, and the resulting b2-receptor/ b-arrestin complex is sequestered from the cell surface and internalized. The receptor is then dephosphorylated, b-arrestin dissociates, and the b2-receptor is recycled back to the membrane. Beta2-AR, b2-adrenergic receptor; Pi, phosphorylation.

In this study, we tried to investigate the link between this desensitization and probability of polymorphism in Beta 2-Adrenergic receptor.

The Arg16/Gln27 receptor underwent 26 ± 3% down-regulation. In contrast, the Gly16/Gln27 receptor displayed 41 ± 3% downregulations. The Gly16/Glu27 receptor displayed a similar level of down-regulation (39 ± 4%) compared to the Gly16/Gln27 receptor. The data suggest that position 16 is the major polymorphic locus that affects agonist-promoted down-regulation [36]. The polymorphism of Beta 2-Adrenergic receptor is at amino acid 164, which can either be threonine (Thr) or isoleucine (Ile). This polymorphism is much rarer than that at amino acid 16 or 27, with an allelic frequency of about 1%, but is potentially interesting in that amino acid 164 is situated in the fourth transmembrane-spanning domain of the receptor and is adjacent to serine 165, which has been predicted to interact with the OH groups of adrenergic ligands [37]. This polymorphism has been studied in a transfected cell system and has been shown to alter the agonist-binding properties of the receptor. Cells expressing Ile 164 were found to have approximately 4 times less ligand affinity. This alteration in binding affinity was reflected in a reduced capacity for the receptor to activate adenylate cyclase, relative to the wild-type (Thr 164) form of the receptor [38]. Association studies have been hampered by the low prevalence of the Thr164Ile polymorphism, which necessitates large patient groups to reach robust conclusions. Piscione et al. now report that Ile164 is much more prevalent in a population of coronary artery disease patients than in a control population (12% vs. 3%), and that within the patient group, Ile164 carriers exhibit a more severe pathology than those with Thr164 genotype. Similarly, a group of patients with peripheral artery disease also exhibited a high prevalence of the Ile164 genotype (7%) and a more severe clinical phenotype than those with Thr164 [39]. However, the Thr164Ile polymorphism may not only have pathophysiological but also therapeutic relevance. Reduced B2AR responses of Ile164 carriers were also reported for lipolysis in isolated adipocytes [40]. Results of this study indicated that in review of gen polymorphism of codon 16, 27, 113 and 164 from beta2 adrenergic receptor, only codon 164 (44.4%) has accompanied with Polycystic Ovary Syndrome. However, the Thr164Ile polymorphism may not only have pathophysiological but also therapeutic relevance [41]. Identification of the candidate genes and understanding of their function holds the promise for the establishment of the specific molecular basis for PCOS. In the future more studies on different populations with a larger sample size are needed for proving of the functional candidate genes that play important role in the etiology of PCOS. We had two limitations in this study: financial obligation and small sample size in control group. The pharmacogenetics studies can help to etiology and drug therapy in PCOS.


  1. Lansdown A, Rees DA (2012) The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target?ClinEndocrinol (Oxf) 77: 791-801.
  2. Stener-Victorin E (2013) Hypothetical physiological and molecular basis for the effect of acupuncture in the treatment of polycystic ovary syndrome.Mol Cell Endocrinol 373: 83-90.
  3. Sverrisdóttir YB,Mogren T, Kataoka J, Janson PO, Stener-Victorin E (2008) Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth?Am J PhysiolEndocrinolMetab 294: E576-581.
  4. Manni L, Cajander S, Lundeberg T, Naylor AS, Aloe L, et al. (2005) Effect of exercise on ovarian morphology and expression of nerve growth factor and alpha(1)- and beta(2)-adrenergic receptors in rats with steroid-induced polycystic ovaries. J Neuroendocrinol 17: 846-858.
  5. Zangeneh FZ,Abdollahi A, Tavassoli P, Naghizadeh MM (2011) The effect of cold stress on polycystic ovary syndrome in rat: before and during modeling.ArchGynecolObstet 284: 651-657.
  6. Aguado L (2002) Role of the central and peripheral nervous system in the ovarian function. J Microsc Res Tech 59: 462-473.
  7. Barria A,Leyton V, Ojeda SR, Lara HE (1993) Ovarian steroidal response to gonadotropins and beta-adrenergic stimulation is enhanced in polycystic ovary syndrome: role of sympathetic innervation.Endocrinology 133: 2696-2703.
  8. Liggett SB (2002) Update on current concepts of the molecular basis of ß2-adrenergic receptor signalling. J Allergy ClinImmunol 110: S223-228.
  9. Xu BY,Arlehag L, Rantapää-Dahlquist SB, Lefvert AK (2005) beta2 Adrenoceptor gene single nucleotide polymorphisms are associated with rheumatoid arthritis in northern Sweden.Ann Rheum Dis 64: 773-776.
  10. Reihsaus E, Innis M, MacIntyre N, Liggett SB (1993) Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects.Am J Respir Cell MolBiol 8: 334-339.
  11. Iaccarino G,Lanni F, Cipolletta E, Trimarco V, Izzo R, et al. (2004) The Glu27 allele of the beta2 adrenergic receptor increases the risk of cardiac hypertrophy in hypertension.JHypertens 22: 2117-2122.
  12. Sethi AA,Tybjaerg-Hansen A, Jensen GB, Nordestgaard BG (2005) 164Ile allele in the beta2-Adrenergic receptor gene is associated with risk of elevated blood pressure in women. The Copenhagen City Heart Study.Pharmacogenet Genomics 15: 633-645.
  13. Atia A, Abdullah A, Alrawaiq N (2014) Overview of the role of ?2-adrenergic receptor variants in human hypertension. International Journal of PharmTech Research 6: 1611-1615.
  14. Bray MS,Boerwinkle E (2000) The role of beta(2)-adrenergic receptor variation in human hypertension.CurrHypertens Rep 2: 39-43.
  15. McGraw DW, Forbes SL, Kramer LA, Liggett SB (1998) Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulates receptor expression. J ClinInves 102: 1927-1932.
  16. Chong LK,Chowdry J, Ghahramani P, Peachell PT (2000) Influence of genetic polymorphisms in the beta2-adrenoceptor on desensitization in human lung mast cells.Pharmacogenetics 10: 153-162.
  17. Candy G, Samani N, Norton G, Woodiwiss A, Radevski I, et al. (2000) Association analysis of beta2 adrenoceptor polymorphisms with hypertension in a Black African population. J Hypertens 18: 167-172.
  18. Waterworth DM, Bennett ST, Gharani N, McCarthy MI, Hague S, et al. (1997) Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome.Lancet 349: 986-990.
  19. Vanková M,Vrbíková J, Hill M, Cinek O, Bendlová B (2002) Association of insulin gene VNTR polymorphism with polycystic ovary syndrome.Ann N Y AcadSci 967: 558-565.
  20. Ferk P,Perme MP, Gersak K (2008) Insulin gene polymorphism in women with polycystic ovary syndrome.JInt Med Res 36: 1180-1187.
  21. Powell BL, Haddad L, Bennett A, Gharani N, Sovio U, et al. (2005) Analysis of multiple data sets reveals no association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits.JClinEndocrinolMetab 90: 2988-2993.
  22. Skrgatic L, Baldani DP, Geršak k, Cerne JZ, Ferk P, et al. (2013) Genetic polymorphisms of INS, INSR and IRS-1 genes are not associated with polycystic ovary syndrome in Croatian women. Collegium Antropologicum 37:141-146.
  23. Yun JH,Gu BH, Kang YB, Choi BC, Song S, et al. (2012) Association between INS-VNTR polymorphism and polycystic ovary syndrome in a Korean population.GynecolEndocrinol 28: 525-528.
  24. Xu Y, Wei Z, Zhang Z, Xing Q, Hu P, et al. (2009) No association of the insulin gene VNTR polymorphism with polycystic ovary syndrome in a Han Chinese population. Reproductive Biology and Endocrinology 7: 141.
  25. Song LY,Luo JR, Peng QL, Wang J, Xie L, et al. (2014) Lack of association of INS VNTR polymorphism with polycystic ovary syndrome: a meta-analysis.J Assist Reprod Genet 31: 675-681.
  26. Shaikh N, Dadachanji R, Mukherjee S (2014) Genetic Markers of Polycystic Ovary Syndrome: Emphasis on Insulin Resistance. International Journal of Medical Genetics. 2014.
  27. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19: 41-47.
  28. Johnson M1 (2006) Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation.J Allergy ClinImmunol 117: 18-24.
  29. Ferruz J, Ahmed CE, Ojeda SR, Lara HE (1992) Norepinephrine release in the immature ovary is regulated by autoreceptors and neuropeptide-Y.Endocrinology 130: 1345-1351.
  30. Lara HE,Ferruz JL, Luza S, Bustamante DA, Borges Y, et al. (1993) Activation of ovarian sympathetic nerves in polycystic ovary syndrome.Endocrinology 133: 2690-2695.
  31. Lara HE, Dorfman M, Venegas M, Luza SM, Luna SL, et al. (2002) Changes in sympathetic nerve activity of the mammalian ovary during a normal estrous cycle and in polycystic ovary syndrome: studies on norepinephrine release. Microsc Res Tech 59:495-502.
  32. Barria A, Leyton V, Ojeda SR, Lara HE (1993) Ovarian steroidal response to gonadotropins and b-adrenergic stimulation is enhanced in polycystic ovary syndrome: role of sympathetic innervation. Endocrinology 133: 2696-2703.
  33. Onaran, HO, Costa T and Rodbard D (1993) Beta gamma subunits of guanine nucleotide-binding proteins and regulation of spontaneous receptor activity: thermodynamic model for the interaction between receptors and guanine nucleotide-binding protein subunits. MolPharmacol 43: 245-256.
  34. Johnson M1 (1998) The beta-adrenoceptor.Am J RespirCrit Care Med 158: S146-153.
  35. Stener-Victorin E, Ploj K, Larsson MB, Holma¨ng A (2005) Rats with steroid-induced polycystic ovaries develops hypertension and increased sympathetic nervous system activity. ReprodBiolEndocrinol 3: 44.
  36. Green S, Turki J, Innis M, Liggett SB (1994) Amino-terminal polymorphisms of the human ß2-adrenergic receptor imparts distinct agonist-promoted regulatory properties. Biochemistry 33: 9414-9419.
  37. Litonjua AA, Gong L, Duan QL, Shin J, Moore MJ, et al. (2010) Very important pharmacogene summary ADRB2.Pharmacogenet Genomics 20: 64-69.
  38. Brodde OE,Büscher R, Tellkamp R, Radke J, Dhein S, et al. (2001) Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors.Circulation 103: 1048-1050.
  39. Piscione F,Iaccarino G, Galasso G, Cipolletta E, Rao MA, et al. (2008) Effects of Ile164 polymorphism of beta2-adrenergic receptor gene on coronary artery disease.J Am CollCardiol 52: 1381-1388.
  40. Hoffstedt J, Iliadou A, Pedersen NL, Schalling M, Arner P (2001) The effect of the beta2 adrenoceptor gene Thr164Ile polymorphism on human adipose tissue lipolytic function. Br J Pharmacol 133: 708-712.
  41. Michel MC, Büscher R (2008) Beta2-adrenergic receptor gene polymorphisms: will the important one please step forward?J Am CollCardiol 52: 1389-1390.
Citation: Jafarian T, Naghizadeh MM, Salmani A, NFathe Moghadam S, Zangeneh FZ (2015) Are beta2-Adrenergic Receptor Gene Single-Nucleotide Polymorphisms Associated with Polycystic Ovary Syndrome? A Pharmacogenetic Study. Gynecol Obstet (Sunnyvale) 5:343.

Copyright: © 2015 Jafarian T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.